LILLE, France, and CAMBRIDGE, Mass., Nov. 2, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that Jean- François Mouney, chairman and CEO of GENFIT, will present the company’s IT-Diab program (Therapeutic Innovation - Diabetes) at the BIO-Europe 2010 partnering conference in Munich.
The presentation will be held at 3.p.m. CET on Nov. 16 and will provide an update on GENFIT’s IT-Diab program, which is dedicated to treating the early stages of the diabetes. Additional updates include its GENFIT’s non- invasive diagnostic biomarkers program for atherosclerosis and other diseases, as well as its therapeutic programs focusing on the role of the circadian rhythm in metabolic disease*.
“We are very proud to present the recent data from our IT-Diab program, including the screening of more than 15,000 patients, at BIO-Europe 2010,” said Jean-François Mouney. ”We also intend to hold discussions about partnerships for the co-development of our diagnostic biomarkers program as well as for our programs focusing on metabolic and inflammatory diseases related to circadian rhythm.”
The 16th annual international partnering conference gathers the leaders of the life science industry and will host more than 2,500 attendees.
- The internal clock system synchronizes daily variations in certain genes expression to rhythms such as sleep and wake alternance, variations in body temperature, blood pressure, heart rate, as well as cognition, attention and mood.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER, …), to address these major public health concerns and their unmet medical needs. GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in Phase II. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Contacts:
GENFIT Jean-François Mouney – CEO & Chairman of the Management Board +33 (0)3 2016 4000 Russo Partners
Martina Schwarzkopf, Ph.D. +1 212 845-4292 / +1 347 591 8785 - martina.schwarzkopf@russopartnersllc.com
MILESTONES – Press Relations Bruno Arabian +33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr
